NGVTNYSEChemicals & Allied ProductsFiscal year ends December 31
Ingevity Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$70.31+0.49 (+0.70%)
Close on Oct 19, 2026
- Market cap
- $2.48B
- P/E (TTM)
- 47.8
- Dividend yield
- –
Ingevity Corp revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PM | $622.20M | $615.50M | $606.90M | $611.90M | $608.00M | $611.30M | $609.60M | $606.20M | $602.30M | $589.70M | $586.00M | $566.00M | 53.6% | +2.3% |
| APT | $168.30M | $162.30M | $160.20M | $167.60M | $178.20M | $182.80M | $188.60M | $187.10M | $181.10M | $186.40M | $204.00M | $221.20M | 14.5% | -5.6% |
| Performance Chemicals | – | $433.50M | $400.50M | $429.90M | $423.90M | $441.50M | $401.90M | $642.90M | $765.00M | $863.50M | $425.50M | $916.80M | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PM | $348.20M | $343.10M | $326.30M | $336.80M | $337.50M | $338.70M | $333.20M | $335.40M | $329.30M | $311.30M | $303.10M | $266.00M | +3.2% |
| APT | $37.50M | $28.30M | $32.10M | $35.40M | $35.30M | $43.10M | $39.00M | $41.50M | $42.90M | $44.70M | $49.00M | $51.20M | +6.2% |
| Performance Chemicals | – | $62.60M | $60.30M | $71.00M | $70.50M | $47.80M | $53.70M | $4.20M | $4.60M | $40.20M | $71.10M | $92.10M | – |
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America | $643.00M | $666.10M | $665.10M | $661.20M | $647.90M | $682.40M | $651.50M | $845.30M | $945.90M | $1.04B | $672.70M | $1.08B | 55.4% | -0.8% |
| United States | $566.80M | $588.70M | $585.00M | $577.70M | $564.50M | $731.30M | $571.50M | – | – | – | – | – | 48.8% | +0.4% |
| Asia Pacific | $305.20M | $302.50M | $298.50M | $308.00M | $316.90M | $328.90M | $325.00M | $306.30M | $316.50M | $316.00M | $323.30M | $365.70M | 26.3% | -3.7% |
| China | $147.40M | $151.60M | $153.10M | $165.00M | $172.60M | $208.50M | $175.60M | – | – | – | – | – | 12.7% | -14.6% |
| South America | $47.20M | $47.30M | $45.10M | $46.30M | $49.90M | $51.40M | $51.20M | $46.00M | $41.70M | $40.80M | $39.60M | $44.70M | 4.1% | -5.4% |
| Europe, Middle East, and Africa | – | – | – | – | – | – | – | – | – | – | – | $215.80M | – | – |
From the segment and revenue-disaggregation notes of Ingevity's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.